top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

Click here now for the full details of this stock that’s set to rocket in the AI revolution…

KA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 29.80%

Insider Buying (Last 12 Months): $100,196.00

Insider Selling (Last 12 Months): $0.00

Kineta Insider Trading History Chart

Kineta Share Price & Price History

^$0.62

▼ -0.05 (-7.46%)

As of 04/24/2024 01:00 AM ET

Days: 30 | 90 | 365

The "Smart Money" Is Ready for May 1st Are You?

From Stansberry Research | Ad

Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.

One Former Wall St. Trader Explains Why…

Kineta Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/6/2023	Raymond J Bartoszek	Director	Buy	250	$4.50	$1,125.00	17,206
12/4/2023	Raymond J Bartoszek	Director	Buy	1,000	$4.33	$4,330.00	15,956
11/28/2023	Craig W Philips	President	Buy	3,000	$3.27	$9,810.00	60,811
11/28/2023	Shawn Iadonato	CEO	Buy	900	$3.33	$2,997.00	671,130
9/20/2023	Craig W Philips	President	Buy	600	$2.54	$1,524.00	54,911
9/20/2023	Pauline Kenny	General Counsel	Buy	1,500	$2.58	$3,870.00	18,448
9/20/2023	Shawn Iadonato	CEO	Buy	10,000	$2.50	$25,000.00	670,230
9/18/2023	Keith Baker	CFO	Buy	5,000	$2.13	$10,650.00	16,880
9/18/2023	Raymond J Bartoszek	Director	Buy	2,500	$2.08	$5,200.00	12,956
9/15/2023	Raymond J Bartoszek	Director	Buy	500	$2.18	$1,090.00	10,456
9/14/2023	Thierry Guillaudeux	Insider	Buy	10,000	$2.00	$20,000.00	21,696
6/16/2023	Keith Baker	CFO	Buy	5,000	$2.92	$14,600.00	11,880
3/20/2023	Craig W Philips	President	Sell	872	$3.29	$2,868.88	66,977
3/20/2023	Pauline Kenny	General Counsel	Sell	544	$3.29	$1,789.76	17,806
3/20/2023	Shawn Iadonato	CEO	Sell	1,119	$3.29	$3,681.51	666,287
3/17/2023	Craig W Philips	President	Sell	1,231	$4.94	$6,081.14	67,849
3/17/2023	Pauline Kenny	General Counsel	Sell	767	$4.94	$3,788.98	18,350
3/17/2023	Shawn Iadonato	CEO	Sell	1,580	$4.94	$7,805.20	667,406

Exposed: 10 CENT Crypto to Explode April 20th?

From True Market Insiders | Ad

Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin

Click For My #1 FREE Crypto for 2024

SEC Filings (Institutional Ownership Changes) for Kineta (NASDAQ:KA)

30.32% of Kineta stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Kineta Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/13/2024	Armistice Capital LLC	825,792	$3M	0.0%	-11.2%	7.948%
11/15/2023	Armistice Capital LLC	930,000	$3.16M	0.0%	+6.2%	8.951%
11/9/2023	Manchester Capital Management LLC	10,216	$35K	0.0%	N/A	0.098%
2/13/2023	Artal Group S.A.	31,055	$0.20M	0.0%	N/A	2.004%

Data available starting January 2016

Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy, which is in preclinical development for advanced solid tumors, such as renal cell carcinoma, ovarian, and colorectal cancers. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. was founded in 2007 and is headquartered in Seattle, Washington.

Today's Range

Now: $0.62

$0.60

$0.67

50 Day Range

MA: $0.98

$0.34

$2.83

52 Week Range

Now: $0.62

$0.33

$5.39

Volume

172,659 shs

Average Volume

298,369 shs

Market Capitalization

$6.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52

Who are the company insiders with the largest holdings of Kineta?: Kineta's top insider investors include:
Shawn Iadonato (CEO)
Craig W Philips (President)
Thierry Guillaudeux (Insider)
Pauline Kenny (General Counsel)
Raymond J Bartoszek (Director)
Keith Baker (CFO)
Learn More about top insider investors at Kineta.